経口抗糖尿病薬の世界市場-2023年～2030年

市場概要

経口抗糖尿病薬の世界市場は、2022年に443億米ドルに達し、2030年には最大808億米ドルに達することで有利な成長を示すと予測されています。世界の経口抗糖尿病薬市場は、予測期間中（2023-2030年）に8.0%のCAGRを示すと予測されます。

患者固有の特性、病歴、治療目的など多くの変数に基づいて、2型糖尿病の治療に使用される特定の経口抗糖尿病薬は患者によって異なります。例えば、カナグリフロジン、ダパグリフロジン、エンパグリフロジンのようなSGLT2阻害薬は、腎臓によるグルコースの再吸収を阻害することで機能し、尿中グルコース排泄量の増加と血糖値の低下を引き起こします。

市場力学

研究活動の活発化が、予測期間中の世界の経口抗糖尿病薬市場の成長を後押ししています

例えば、2022年12月、ファイザーは、Gタンパク質共役受容体（GPCR）に焦点を当てた構造ベース薬物設計（SBDD）および開発の世界的リーダーであるそーせいグループ株式会社に、ファイザーの候補薬PF-07081532が第2相臨床試験で最初の被験者に投与されたことを通知しました。この目標に達した場合、そーせいヘプタレス社は1,000万米ドルの支払いを受けます。

次世代経口低分子GLP-1受容体作動薬PF-07081532は、1日1回投与の2型糖尿病および肥満症治療薬として開発されています。ファイザーは、そーせいヘプタレのユニークなStaR（安定化受容体）技術を利用できるマルチターゲット研究協力において、ファイザーの科学者がPF-07081532を発見しました。ファイザーが実施したPF-07081532の第1相臨床試験は成功しました。

認知度の向上と政府の取り組みが、予測期間中の世界の経口抗糖尿病薬市場の成長を後押ししています

世界最大の糖尿病啓発キャンペーンである「世界糖尿病デー」は、160カ国以上で10億人以上の人々が参加します。この日を記念する主な目的は、糖尿病に対する認識を高め、この世界の健康上の大きな懸念に対処するための行動を人々に促すことです。2021-23年の世界糖尿病デーでは、「糖尿病治療へのアクセス」が焦点となります。"明日を守る教育"は、世界糖尿病デー2021-23キャンペーンの2年目の焦点です。

2022年のキャンペーンでは、医療従事者と糖尿病患者にとって、質の高い糖尿病教育へのアクセシビリティの向上が求められていることが強調されました。活動では、医療従事者と糖尿病患者が質の高い糖尿病教育を受けられるように改善することの重要性が強調されます。

個別化薬が経口抗糖尿病薬市場の成長機会をもたらす

データサイエンスとテクノロジーの急速な発展により、治療や予防介入の精度が向上し、適切な患者に適切なタイミングで適切な治療を推奨できるようになる可能性があります。2型糖尿病は複雑で異質な多遺伝子性代謝疾患であるため、"one size fits all"戦略は有効ではないです。

遺伝学、ゲノミクス、プロテオミクス、メタボロミクスの技術的進歩により、何千もの遺伝子、タンパク質、代謝産物の効率的な解析が可能になっています。このことは、糖尿病のような様々なサブタイプの疾患に関連する遺伝的要因や遺伝子産物を同定する新たな機会を提示しています。

COVID-19の影響分析

COVID-19の流行は経口抗糖尿病薬市場に大きな影響を与えています。COVID-19の結果、医療機関への受診が減少し、遠隔ヘルスケアサービスへの依存が高まるなど、患者の行動が変化しました。一部の糖尿病患者は経口抗糖尿病薬を入手するのが難しくなったり、治療計画を守るのが難しくなったりしたため、これらの薬剤の需要に影響が出た可能性があります。

2023年現在、COVID-19の状況は回復しており、すべてのヘルスケア施設が患者にとって利用しやすく、適切な治療を行うことができるため、世界中で経口抗糖尿病薬の需要が増加しています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争が経口抗糖尿病薬市場に与える影響は複雑で多面的です。紛争の結果、人々が自宅から避難したり、他の場所に安全を求めたりせざるを得なくなり、人口移動が発生する可能性があります。避難民にとってヘルスケアサービス、特に経口抗糖尿病薬へのアクセスは困難であり、糖尿病管理が中断される可能性があります。ロシアとウクライナはともに、紛争による経済的悪影響を被っています。個人にとってもヘルスケアシステムにとっても、経口抗糖尿病薬の価格設定と入手可能性は、経済的不安定、通貨変動、インフレ圧力の影響を受けています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 糖尿病有病率の増加
  • 抑制要因
    • 糖尿病治療薬に伴う副作用
  • 機会
    • 技術の進歩
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 製品別

• ビグアナイド
  • メトホルミン
• α-グルコシダーゼ阻害薬
• ドーパミン-D2受容体作動薬
  • ブロモクリプチン（シクロセット）
  • ナトリウム-グルコース共輸送担体-2（SGLT-2）阻害薬
  • インボカーナ（カナグリフロジン）
  • ジャーディアンス（エンパグリフロジン）
  • ファルキシガ／フォルキシガ（ダパグリフロジン）
  • スグラット（イプラグリフロジン）
• ジペプチジルペプチダーゼ4（DPP-4）阻害薬
  • ジャヌビア（シタグリプチン）
  • オングリザ（サキサグリプチン）
  • トラジェンタ（リナグリプチン）
  • ビピディア/ネシーナ（アログリプチン）
  • ガルバス（ビルダグリプチン）
• スルホニル尿素
• メグリチニド

第10章 剤形別

• 液剤
• カプセル剤
• 錠剤

第11章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• Glenmark Pharma
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Abbott
• Biocon
• Sanofi
• Sunpharma
• Novartis
• Novo Nordisk
• Merck
• GlaxoSmithKline
• Bristol-Myers Squibb

第15章 付録

Market Overview

The global Oral Anti-Diabetic Drugs Market reached US$ 44.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 80.8 billion by 2030. The global oral anti-diabetic drugs market is expected to exhibit a CAGR of 8.0% during the forecast period (2023-2030).

Based on a number of variables, such as the patient's unique characteristics, medical history, and treatment objectives, the specific oral anti-diabetic medications used in the treatment of type 2 diabetes vary in patients. For instance, SGLT2 inhibitors like canagliflozin, dapagliflozin, and empagliflozin function by preventing the kidneys' reabsorption of glucose, which causes an increase in urine glucose excretion and a decrease in blood sugar levels.

Market Dynamics

The Increasing Research Activities Are Boosting The Global Oral Anti-Diabetic Drugs Market Growth During The Forecast Period.

For instance, in December 2022, Pfizer notified Sosei Group Corporation, a global leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, that the candidate medicine PF-07081532 from Pfizer has been dosed to the first subject in Phase 2 clinical trial. When this goal is reached, Sosei Heptares will get a payment of $10 million USD.

Next-generation oral small molecule GLP-1 receptor agonist PF-07081532 is being developed as a once-daily treatment for Type 2 diabetes and obesity. In multi-target research cooperation where Pfizer has access to Sosei Heptare's unique StaR (stabilized receptor) technology, Pfizer scientists made the discovery of PF-07081532. The Pfizer-conducted Phase 1 clinical trial for PF-07081532 was successful.

The Growing Awareness And Government Initiatives Are Boosting The Global Oral Anti-Diabetic Drugs Market Growth During The Forecast Period.

The largest diabetes awareness campaign in the world, World Diabetes Day reaches over one billion individuals in more than 160 countries. The primary goal of honoring this day is to raise awareness of diabetes and encourage people to take action to address this major global health concern. Access to Diabetes Care is the focus of World Diabetes Day 2021-23. "Education to Protect Tomorrow" is the focus of the World Diabetes Day 2021-23 campaign's second year.

The emphasis of the campaign 2022 was on the requirement for improved accessibility to high-quality diabetes education for medical professionals and diabetic patients. Activities will emphasize the importance of improving health professionals' and diabetes patients' access to high-quality diabetes education.

Personalized Medicines Provide Oral Anti-Diabetic Drugs Market Growth Opportunities

Rapid developments in data science and technology have the potential to increase the accuracy of therapeutic and preventative interventions and make it possible to recommend the correct treatment to the right patient at the right time. A "one size fits all" strategy is ineffective for treating type 2 diabetes since it is a complex, heterogeneous, and polygenic palette of metabolic diseases.

The efficient analysis of thousands of genes, proteins, and metabolites is now possible due to technological advancements in genetics, genomics, proteomics, and metabolomics. This presents new opportunities for identifying genetic factors and gene products that are linked to various subtypes of diseases, such as diabetes mellitus.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the oral anti-diabetic drugs market. Patient behavior has changed as a result of COVID-19, including a decrease in visits to medical facilities and an increase in reliance on remote healthcare services. The demand for these medications may have been impacted because some diabetics may have had trouble getting access to oral anti-diabetes medications or sticking to their treatment plans.

As of 2023, the COVID-19 situation is recovering and all healthcare facilities are accessible for patients and can give proper treatment leading o increasing demand for oral anti-diabetic drugs worldwide.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the oral anti-diabetic drugs market is complex and multifaceted. Population displacement may occur as a result of the conflict because people may be compelled to evacuate their homes or seek safety elsewhere. Access to healthcare services, especially oral diabetes medications, is difficult for displaced people, which could interrupt the management of their diabetes. Both Russia and Ukraine have had negative economic impacts from the conflict. The pricing and availability of oral anti-diabetes medications for both individuals and healthcare systems are impacted by economic instability, currency fluctuations, and inflationary pressures.

Segment Analysis

The global oral anti-diabetic drugs market is segmented based on drug class, dosage type, distribution channel, and region.

The Dopamine -D2 Receptor Agonist Segment Is Expected To Hold A Position In The Market Over The Forecast Period.

The Dopamine -D2 receptor agonist segment accounted for 26.5% market share in the Oral Anti-Diabetic Drugs market in 2022. The research provides insights into the exact mechanism by which bromocriptine mesylate enhances glycemic control. However, it has been demonstrated that bromocriptine mesylate treatment in the morning improves glycemic control in T2D patients without raising plasma insulin concentrations.

This might be connected to the diurnal peak in central dopaminergic tone brought on by morning administration of the quick-release bromocriptine formulation in the brain regions that control peripheral fuel metabolism (including glucose, lipid metabolism, and protein metabolism).

Geographical Analysis

Increasing Collaborations And Partnerships Among The Key Players And Increasing Product Launches Dominate the Asia Pacific Region.

Asia Pacific is expected to dominate the oral anti-diabetic drugs market, accounting for around 24.4% of this market. For instance, in January 2022, earlier exclusively available as injections anti-diabetic medication has now been made available orally by Novo Nordisk India. The company reported that the new medication can help adults with type-2 diabetes better regulate their weight and blood sugar levels.

A naturally occurring hormone called glucagon-like peptide 1 is crucial in preserving the proper level of blood glucose. The only problem with peptide and protein-based biological treatments is that they must be administered intravenously, despite the fact that they are often quite successful.

Competitive Landscape

The major global players in the market include: Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, and Bristol-Myers Squibb among others.

Why Purchase the Report?

• To visualize the global oral anti-diabetic drugs market segmentation based on the drug class, dosage type, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of oral anti-diabetic drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global oral anti-diabetic drugs market report would provide approximately 62 tables, 61 figures, and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Dosage Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of diabetes
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with diabetic drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological advancements
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.1.2. Market Attractiveness Index, By Product
  • 9.1.3. Biguanides*
  • 9.1.4. Introduction
  • 9.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.1.5.1. Metformin
  • 9.1.6. Alpha-glucosidase inhibitors
  • 9.1.7. Dopamine -D2 Receptor Agonist
    • 9.1.7.1. Bromocriptin (Cycloset)
    • 9.1.7.2. Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
    • 9.1.7.3. Invokana (Canagliflozin)
    • 9.1.7.4. Jardiance (Empagliflozin)
    • 9.1.7.5. Farxiga/Forxiga (Dapagliflozin)
    • 9.1.7.6. Suglat (Ipragliflozin)
  • 9.1.8. Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
    • 9.1.8.1. Januvia (Sitagliptin)
    • 9.1.8.2. Onglyza (Saxagliptin)
    • 9.1.8.3. Tradjenta (Linagliptin)
    • 9.1.8.4. Vipidia/Nesina (Alogliptin)
    • 9.1.8.5. Galvus (Vildagliptin)
  • 9.1.9. Sulfonylureas
  • 9.1.10. Meglitinides

10. By Dosage Type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 10.1.2. Market Attractiveness Index, By Dosage Type
• 10.2. Liquid*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Capsule
• 10.4. Tablet

11. By Distribution Channel

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
• 11.1.2. Market Attractiveness Index, By Distribution Channel
• 11.2. Hospital Pharmacies*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Retail Pharmacies
• 11.4. Online Pharmacies

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. The U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. The U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Glenmark Pharma*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Abbott
• 14.3. Biocon
• 14.4. Sanofi
• 14.5. Sunpharma
• 14.6. Novartis
• 14.7. Novo Nordisk
• 14.8. Merck
• 14.9. GlaxoSmithKline
• 14.10. Bristol-Myers Squibb

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us